FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors July 1, 2024
FDA places partial clinical hold on Ph 1 ZN-c3-001 in solid tumors, Ph 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and Ph 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC) of azenosertib June 25, 2024
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage ADC Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers June 25, 2024
EMA validates extension application for SC formulation for Opdivo including liquid formulation and new strength across previously approved indications June 25, 2024
Lead Selection for MDG2021 Announced, Expanding TCR-T KRAS Library Targeting Solid Tumors June 25, 2024
China’s NMPA approves IND for GFH375 for Ph 1/2 Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation June 25, 2024
US FDA Approves Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors June 18, 2024
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors June 18, 2024
IND Filing for PFL-002/VERT-002 for Patients with Solid Tumors Including NSCLC with MET Alterations June 11, 2024
Adaptimmune and Galapagos Collaborate on uza-cel in Head & Neck Cancer and Potential Future Solid Tumor Indications June 4, 2024
Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial June 4, 2024
First Patient Dosed in Global Tumor-Agnostic Ph 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors June 3, 2024
FDA Updates Action Date for Subcutaneous Nivolumab (nivolumab and hyaluronidase); new PDUFA: December 29, 2024 May 29, 2024
Dragonfly Announces Clinical Collaboration to Evaluate DF9001 in Combination with KEYTRUDA® in Patients with Solid Tumors May 29, 2024
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases May 29, 2024
